Description
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize medicines and technologies. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 8 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. In addition to a robust clinical stage pipeline, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
We embrace diversity across all dimensions and levels of the organization, and we strive to ensure every employee is supported in reaching their full potential. We hire motivated people with diverse backgrounds, identities, experiences and skillsets. We are committed to fostering an inclusive culture where all employees feel valued, respected and empowered to create value for patients.
To learn more about our story and company culture, please visit us at https://roivant.com/
Position Summary
The Principal, Data & Analytics will own the statistical and quantitative work that connects clinical evidence to the most important decisions Roivant makes across its pipeline. This is not a strategy role — this is a figure-things-out and get-things-done role in a high-stakes environment with substantial ownership. We expect you to get to ground truth on the hardest clinical and scientific questions the company faces, working directly in trial datasets and translating rigorous analysis into recommendations that leadership acts on.
The Principal will pressure-test the clinical assumptions underpinning key pipeline and commercial decisions, build the statistical frameworks needed to evaluate evidence across assets, and ensure Roivant has a clear-eyed view of what its data actually shows. The scope is intentionally broad and is well-suited to a high-potential individual earlier in their career with exceptional upside and a strong desire to take on responsibility.
Responsibilities
Clinical Trial Data & Signal Detection
- Work directly in ongoing and completed clinical trial datasets (CSRs, patient-level data, interim readouts) to identify efficacy signals, safety patterns, and subgroup effects that inform go/no-go and commercialization decisions
- Build rigorous statistical analyses from scratch: mixed-effects models, longitudinal models, Bayesian frameworks, subgroup analyses, and sensitivity analyses across Roivant's pipeline assets
- Monitor emerging safety signals and unexpected findings in real time across ongoing studies; surface and contextualize them for leadership before they become surprises
- Pressure-test clinical assumptions: challenge endpoint choices, scrutinize statistical analysis plans, and flag where the data does not support the narrative
- Execute focused 1-5 day analytical sprints on the highest-priority questions from Roivant and Vant leadership
Evidence Synthesis & Competitive Intelligence
- Develop a deep, differentiated read of the clinical evidence base for Roivant's near-commercial assets: what the data shows, what it does not, and where the science is genuinely uncertain
- Analyze competitors' trial data, published and unpublished, with the same rigor applied to Roivant's own: endpoints, patient populations, effect sizes, and durability
- Synthesize findings from literature, registries, claims, and proprietary datasets into coherent evidence narratives that hold up under scrutiny
Data Infrastructure & Cross-Platform Work
- Drive selection and integration of the data sources needed to support portfolio decisions, including claims, labs, clinical trial data, and genomics
- Help build shared analytical infrastructure across Roivant and Vant companies
- Identify opportunities to apply consistent statistical frameworks across assets and therapeutic areas
Qualifications
- Exceptional record of achievement from a top-tier university
- Outstanding analytical ability and a relentless drive to get to the right answer; you do not stop at a plausible one
- Strong quantitative foundation and fluency with data; you have used both to answer hard questions under pressure, not just to describe what happened
- Genuine curiosity about science, medicine, or health; deep biology training is not required, but the underlying questions need to matter to you
- Fast learner who gets up to speed in unfamiliar domains without needing a runway; you are comfortable operating at the edge of your knowledge
- A track record of doing work that changed a decision or outcome, not just informed one
- Able to communicate complex findings with clarity and confidence to senior stakeholders across disciplines
Context
Roivant is preparing to become the next breakout commercial-stage biotech, with the commercialization of brepocitinib, IMVT-1402, and mosliciguat. Getting those launches right requires an unusually rigorous understanding of the clinical evidence that defines each market: what the data actually shows, not what anyone wishes it showed.
This role ensures that understanding exists. It carries real ownership, direct exposure to senior leadership, and a trajectory that can serve as a foundation for future senior roles across the platform.
Compensation & Benefits
This is a full-time position. The role offers meaningful equity participation and a comprehensive company-sponsored benefits package.
Base salary will be determined during the interview process and will vary based on multiple factors, including prior experience, relevant expertise, current business needs, and market conditions. The expected base salary will generally be between $130,000 to $220,000 per year at commencement of employment, but the final salary offered may be outside this range based on individual circumstances.
This position is at-will and Roivant reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance and business and market conditions.
Roivant Sciences provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
We will not accept unsolicited resumes nor outreach from agencies. Please do not send agency resumes to our website or Roivant Sciences and affiliated employees. Thanks!
Similar jobs
Est. 132,500 USD
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiar…
Est. 175,000 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 155,000 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 142,500 USD
Since its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companie…
Est. 100,000 USD
About Roivant Sciences Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by cr…
Est. 158,500 USD
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant advances its pipeline by creating nimble subsidiar…
Est. 233,500 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 282,500 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 209,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 150,000 USD
PhaseV is transforming clinical development through advanced AI and ML. With rapidly growing demand from top pharma, biotech companies, and CROs, we’re seeking a Senior Director of Business Development to help support an…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 226,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 237,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 317,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 282,500 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 298,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 371,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 140,000 USD
For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. Our commercial portfolio includes treatments…
Est. 211,500 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 211,500 USD
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clini…
Est. 317,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 371,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 298,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 199,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 330,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…